Warning: fopen(/home/virtual/epih/journal/upload/ip_log/ip_log_2024-12.txt): failed to open stream: Permission denied in /home/virtual/lib/view_data.php on line 95 Warning: fwrite() expects parameter 1 to be resource, boolean given in /home/virtual/lib/view_data.php on line 96
1Department of Epidemiology, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran
2Department of Biostatistics, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran
3Modeling of Noncommunicable Diseases Research Center, Department of Biostatistics and Epidemiology, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran
4HIV/AIDS Research Centre, Shiraz University of Medical Sciences, Shiraz, Iran
5Iranian Research Center of HIV & AIDS, Tehran University of Medical Sciences, Tehran, Iran
6Social Determinants of Health Research Center, School of Public Health, Hamadan University of Medical Sciences, Hamadan, Iran
©2018, Korean Society of Epidemiology
This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Characteristics | n (%) |
---|---|
Gender | |
Men | 22,507 (83.6) |
Women | 5,009 (16.4) |
Age (yr) | |
0-4 | 349 (1.1) |
5-14 | 175 (0.5) |
15-24 | 3,188 (10.4) |
25-34 | 14,089 (46.1) |
35-44 | 9,076 (29.7) |
45-54 | 2,937 (9.6) |
55-64 | 593 (1.9) |
≥65 | 109 (0.3) |
Marriage status | |
Married | 10,138 (33.2) |
Single | 10,676 (34.9) |
Divorced or widowed | 4,941 (16.1) |
Unknown | 4,761 (15.6) |
Transmission | |
IDU | 20,415 (66.9) |
Unsafe sexual contact | 5,767 (18.9) |
Blood transfusion | 214 (0.7) |
Mother-to-child | 488 (1.6) |
Unknown | 3,661 (12.0) |
WHO disease stage | |
I | 8,046 (57.9) |
II | 2,323 (16.0) |
III | 2,305 (16.6) |
IV | 1,293 (9.3) |
Co-infection of HIV and TB | |
Positive | 1,136 (3.7) |
Negative | 10,659 (34.9) |
Unknown | 18,721 (61.3) |
CD4 cell count at baseline (cells/mm3) | |
≤200 | 1,658 (37.6) |
201-349 | 891 (20.2) |
350-499 | 731 (16.6) |
≥500 | 1,126 (25.5) |
Antiretroviral therapy | |
Yes | 10,288 (33.7) |
No | 20,228 (66.2) |
Prognosis | |
Alive | 9,613 (31.5) |
Censored | 12,708 (41.6) |
Died | 8,195 (26.8) |
Variables | 20-24 | 25-29 | 30-34 | 35-39 | 40-44 | 45-49 | 50-54 | 55-59 | 60-64 | ≥65 |
---|---|---|---|---|---|---|---|---|---|---|
Overall life expectancy in Iran (2015) [17] | 56.1 | 51.5 | 46.8 | 42.1 | 37.3 | 32.6 | 28.0 | 23.6 | 19.3 | 15.2 |
Overall in HIV/AIDS patients | 23.1 (22.6, 23.5) | 19.7 (19.3, 20.0) | 16.9 (16.5, 17.3) | 14.5 (14.1, 14.9) | 12.6 (12.1, 13.0) | 10.7 (10.2, 11.2) | 8.9 (8.4, 9.5) | 7.5 (7.0, 8.1) | 5.5 (5.0, 6.0) | 2.5 (2.2, 2.7) |
Men | 21.6 (21.1, 22.0) | 18.4 (18.0, 18.8) | 15.8 (15.4, 16.2) | 13.5 (13.1, 13.9) | 11.7 (11.2, 12.1) | 9.9 (9.3, 10.4) | 8.2 (7.6, 8.8) | 6.8 (6.1, 7.4) | 5.3 (4.7, 6.0) | 2.5 (2.1, 2.8) |
Women | 32.7 (31.4, 34.0) | 28.3 (27.1, 29.6) | 24.6 (23.4, 25.8) | 20.9 (19.6, 22.1) | 17.6 (16.3, 18.7) | 14.6 (13.4, 15.9) | 11.2 (10.0, 12.5) | 9.6 (8.5, 10.7) | 6.0 (5.0, 6.9) | 2.5 (2.2, 2.7) |
Marriage status | ||||||||||
Married | 25.5 (24.8, 26.2) | 21.5 (20.9, 22.1) | 17.9 (17.4, 18.5) | 15.2 (14.6, 15.80) | 12.9 (12.2, 13.5) | 10.5 (9.8, 11.1) | 8.8 (8.1, 9.6) | 7.3 (6.5, 8.1) | 5.4 (4.7, 6.2) | 2.5 (2.1, 2.9) |
Single | 20.3 (19.6, 20.9) | 17.0 (16.4, 17.6) | 14.5 (13.8, 15.1) | 12.2 (11.5, 12.9) | 10.4 (9.5, 11.2) | 9.3 (8.2, 10.4) | 7.2 (5.9, 8.5) | 5.2 (3.5, 6.8) | 4.2 (3.0, 5.3) | 2.5 (2.2, 2.7) |
Divorced or widowed | 27.9 (26.9, 29.0) | 23.7 (22.8, 24.6) | 20.3 (19.4, 21.2) | 17.1 (16.2, 18.0) | 14.9 (13.9, 15.8) | 12.8 (11.7, 13.8) | 10.8 (9.7, 11.9) | 9.5 (8.5, 10.5) | 6.2 (5.5, 7.0) | 2.5 (2.1, 2.8) |
Unknown | 13.1 (11.8, 14.5) | 10.5 (9.5, 11.5) | 9.0 (8.0, 9.9) | 8.2 (7.2, 9.2) | 7.6 (6.5, 8.7) | 6.3 (5.3, 7.4) | 3.8 (2.9, 4.7) | 3.0 (2.7, 3.4) | 2.8 (2.4, 3.1) | 2.5 (2.2, 2.7) |
WHO disease stage | ||||||||||
I | 38.1 (37.1, 39.1) | 33.7 (32.8, 34.7) | 29.8 (28.8, 30.8) | 25.6 (24.6, 26.5) | 21.9 (20.9, 22.9) | 18.4 (17.4, 19.4) | 14.7 (13.7, 15.7) | 11.1 (10.2, 12.0) | 7.0 (6.2, 7.7) | 2.5 (1.9, 3.0) |
II | 37.7 (35.9, 39.5) | 33.3 (31.5, 35.0) | 28.6 (26.8, 30.4) | 24.5 (22.7, 26.2) | 20.7 (18.9, 22.5) | 17.1 (15.3, 19.0) | 13.8 (11.9, 15.6) | 10.2 (8.6, 11.9) | 6.8 (5.4, 8.2) | 2.5 (1.6, 3.3) |
III | 24.6 (23.4, 25.8) | 20.4 (19.3, 21.5) | 17.3 (16.2, 18.4) | 14.4 (13.3, 15.5) | 12.1 (10.9, 13.3) | 9.8 (8.5, 11.1) | 8.1 (6.6, 9.6) | 8.0 (6.3, 9.6) | 5.7 (4.1, 7.2) | 2.5 (1.7, 3.2) |
IV | 24.8 (23.3, 26.4) | 20.5 (19.1, 21.8) | 16.8 (15.4, 18.2) | 14.1 (12.7, 15.5) | 11.6 (10.2, 13.1) | 9.0 (7.4, 10.7) | 7.3 (5.5, 9.2) | 6.7 (4.6, 8.8) | 6.1 (4.6, 7.6) | 2.5 (1.4, 3.5) |
Co-infection of HIV and TB | ||||||||||
TB-positive | 21.6 (20.4, 22.9) | 17.1 (16.0, 18.3) | 14.1 (13.0, 15.2) | 11.5 (10.4, 12.5) | 9.5 (8.4, 10.5) | 6.7 (5.6, 7.7) | 3.4 (2.3, 4.6) | 4.5 (2.5, 6.5) | 3.7 (1.6,5.8) | 2.5 (1.8, 3.1) |
TB-negative | 36.5 (35.7, 37.4) | 32.1 (31.3, 32.9) | 27.9 (27.1, 28.7) | 23.9 (23.1, 24.7) | 20.4 (19.4, 21.3) | 16.9 (16.1, 17.8) | 13.8 (13.0, 14.7) | 10.6 (9.8, 11.4) | 7.0 (6.3, 7.6) | 2.5 (1.5, 3.0) |
CD4 count at baseline (cells/mm3) | ||||||||||
≤200 | 17.8 (15.5, 20.2) | 15.2 (13.6, 16.8) | 14.5 (13.2, 15.7) | 12.7 (11.4, 14.0) | 11.5 (10.1, 12.9) | 10.5 (9.0, 12.0) | 8.5 (6.9, 10.1) | 9.0 (7.4, 10.5) | 5.8 (4.4, 7.2) | 2.5 (1.7, 3.2) |
>200 | 32.8 (30.8, 34.7) | 29.0 (27.2, 30.9) | 25.5 (23.7, 27.4) | 21.6 (19.8, 23.5) | 18.2 (16.3, 20.1) | 15.6 (13.7, 17.5) | 12.4 (10.5, 14.3) | 10.0 (8.3, 11.6) | 6.4 (5.0, 7.9) | 2.5 (1.6, 3.4) |
Antiretroviral therapy | ||||||||||
Yes | 37.0 (36.2, 37.8) | 32.4 (31.6, 33.2) | 28.0 (27.2, 28.8) | 23.9 (23.1, 24.6) | 20.3 (19.5, 21.1) | 16.6 (15.8, 17.5) | 13.2 (12.4, 14.0) | 10.5 (9.7, 11.2) | 6.6 (5.9, 7.2) | 2.5 (2.1, 2.9) |
No | 15.5 (15.1, 15.9) | 12.5 (12.2, 12.8) | 10.4 (10.1, 10.7) | 8.8 (8.5, 9.1) | 7.5 (7.2, 7.9) | 6.3 (5.9, 6.6) | 4.8 (4.4, 5.3) | 3.9 (3.3, 4.4) | 3.7 (3.0, 4.4) | 2.5 (1.8, 3.0) |
Transmission | ||||||||||
IDU | 21.0 (20.8, 21.1) | 17.8 (17.6, 17.9) | 15.0 (14.9, 15.2) | 12.7 (12.5, 12.9) | 10.7 (10.4, 11.0) | 8.8 (8.6, 8.9) | 7.1 (6.9, 7.2) | 5.5 (5.4, 5.6) | 4.6 (4.5, 4.7) | 2.5 (2.4, 2.5) |
Unsafe sexual contact | 31.4 (30.3, 32.4) | 27.2 (26.2, 28.3) | 23.9 (22.8, 24.9) | 20.2 (19.1, 21.3) | 17.2 (16.1, 18.3) | 14.3 (13.2, 15.4) | 11.5 (10.4, 12.6) | 9.4 (8.5, 10.3) | 6.1 (5.3, 6.8) | 2.5 (2.4, 2.5) |
Province | Life expectancy (yr) | 95% CI |
|
---|---|---|---|
LL | UL | ||
Tehran | 31.4 | 30.2 | 32.6 |
Semnan | 30.3 | 17.6 | 43.0 |
Qom | 28.6 | 26.3 | 31.0 |
Markazi | 25.8 | 24.4 | 27.3) |
Yazd | 25.3 | 21.4 | 29.2 |
Mazandaran | 25.0 | 21.5 | 28.5 |
Qazvin | 24.3 | 21.7 | 26.9 |
Isfahan | 24.2 | 22.3 | 26.1 |
Khorasan | 23.8 | 21.8 | 25.8 |
Bushehr | 23.3 | 20.8 | 25.5 |
Kermanshah | 22.9 | 21.7 | 24.1 |
Fars | 22.5 | 21.6 | 23.4 |
Kurdistan | 21.7 | 19.5 | 23.8 |
Alborz | 21.3 | 19.0 | 23.7 |
Hamadan | 21.2 | 19.4 | 23.0 |
East Azerbaijan | 21.2 | 19.4 | 22.9 |
Hormozgan | 20.0 | 18.3 | 21.7 |
Khozestan | 19.9 | 18.6 | 21.2 |
Chaharmahal and Bakhtiari | 19.9 | 16.4 | 23.3 |
Golestan | 19.1 | 17.7 | 20.5 |
Ardebil | 19.1 | 13.3 | 24.9 |
Zanjan | 18.8 | 15.6 | 22.0 |
West Azerbaijan | 17.6 | 15.9 | 19.2 |
Kerman | 17.6 | 14.3 | 20.8 |
Lorestan | 17.4 | 16.5 | 18.3 |
Sistan and Baluchestan | 17.4 | 14.8 | 19.8 |
Qilan | 16.8 | 14.4 | 19.2 |
Ilam | 14.7 | 12.6 | 16.8 |
Kohgiluyeh and Boyer-Ahmad | 13.2 | 11.6 | 14.8 |
National | 23.1 | 22.6 | 23.5 |
HIV, human immunodeficiency virus; IDU, injection drug use; WHO, World Health Organization; TB, tuberculosis.
HIV, human immunodeficiency virus; WHO, World Health Organization; TB, tuberculosis; IDU, injection drug use.
HIV, human immunodeficiency virus; CI, confidence interval; LL, lower limit; UL, upper limit.